公开(公告)号：US20180327488A1

公开(公告)日：2018-11-15

申请号：US16044636

申请日：2018-07-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Silvia CARVALHO ,  Moshit LINDZEN

IPC: C07K16/22 ,  A61K45/06 ,  A61K31/704 ,  A61K33/24

CPC classification number: C07K16/22 ,  A61K31/704 ,  A61K33/24 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  G01N33/57407 ,  G01N33/57449 ,  G01N2033/57461 ,  G01N2333/485 ,  G01N2333/495 ,  G01N2800/52

Abstract: A method of determining the suitability of a subject to a treatment with an anti-amphiregulin antibody, wherein the subject has a cancer selected from the group consisting of ovarian cancer, head and neck cancer and pancreatic cancer exhibiting resistance to chemotherapy, is provided. The method comprising analyzing in a biological sample of the subject expression level of amphiregulin, transforming growth factor alpha (TGF-alpha) and heparin-binding epidermal growth factor (HB-EGF), wherein a level of expression of the amphiregulin above a predetermined threshold and no expression of the TGF-alpha and/or the HB-EGF or an expression below a predetermined level of the TGF-alpha and/or the HB-EGF is indicative of the suitability of the subject to treatment with the anti-amphiregulin antibody. Methods for treating cancer are also provided, as well as antibodies and pharmaceutical compositions.

公开(公告)号：US20170306049A1

公开(公告)日：2017-10-26

申请号：US15508112

申请日：2015-09-08

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Yosef YARDEN ,  Nadège GABORIT ,  Moshit LINDZEN

IPC: C07K16/32 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a KD value of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HERS and NRG-induced cancer cell migration and proliferation.

公开(公告)号：US20170002068A1

公开(公告)日：2017-01-05

申请号：US15271515

申请日：2016-09-21

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Silvia CARVALHO ,  Moshit LINDZEN

IPC: C07K16/22 ,  G01N33/574 ,  A61K31/704 ,  A61K45/06 ,  A61K33/24

CPC classification number: C07K16/22 ,  A61K31/704 ,  A61K33/24 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  G01N33/57407 ,  G01N33/57438 ,  G01N33/57449 ,  G01N2333/485 ,  G01N2333/495 ,  G01N2800/52

Abstract: A method of determining the suitability of a subject to a treatment with an anti-amphiregulin antibody, wherein the subject has a cancer selected from the group consisting of ovarian cancer, head and neck cancer and pancreatic cancer exhibiting resistance to chemotherapy, is provided. The method comprising analyzing in a biological sample of the subject expression level of amphiregulin, transforming growth factor alpha (TGF-alpha) and heparin-binding epidermal growth factor (HB-EGF), wherein a level of expression of the amphiregulin above a predetermined threshold and no expression of the TGF-alpha and/or the HB-EGF or an expression below a predetermined level of the TGF-alpha and/or the HB-EGF is indicative of the suitability of the subject to treatment with the anti-amphiregulin antibody. Methods for treating cancer are also provided, as well as antibodies and pharmaceutical compositions.

Abstract translation: 本发明提供一种测定受试者用抗双抗调素抗体治疗的适应性的方法，其中所述受试者具有选自卵巢癌，头颈部癌症和表现出抗化学疗法的胰腺癌的癌症。 所述方法包括在生物样品中分析双调蛋白，转化生长因子α（TGF-α）和肝素结合表皮生长因子（HB-EGF）的受试者表达水平，其中所述双调蛋白的表达水平高于预定阈值 并且TGF-α和/或HB-EGF的表达或低于TGF-α和/或HB-EGF的预定水平的表达不表示受试者用抗两性调节蛋白抗体治疗的适合性 。 还提供了治疗癌症的方法，以及抗体和药物组合物。